Neuromod, headquartered in the Digital Hub, Dublin, Ireland, is an emerging medical technology company, specialising in the design and development of multimodal non-invasive neuromodulation technologies to address the clinical needs of underserved patient populations who live with chronic neurological conditions. Neuromod has conducted extensive clinical trials to confirm the efficacy of its non-invasive neuromodulation treatment for Tinnitus (Lenire®), a condition that affects between 10 and 15% of the global population. Lenire® is CE marked and commercial roll out is underway.
Lenire® is the first non-invasive bimodal neuromodulation tinnitus treatment to soothe and relieve tinnitus.
Lenire® has CE-mark certification for the treatment of tinnitus under the supervision of an appropriately qualified healthcare professional in Europe. Lenire® is not approved for sale outside of Europe.
Lenire™ has three main parts. The controller is a lightweight, handheld device that controls the duration and intensity of the treatment. The tonguetip® is connected to the controller and delivers mild energy pulses to the tongue. Bluetooth headphones deliver the audio (sound) part of the treatment..
Lenire® is the only tinnitus treatment device that has achieved consistent results in multiple prospective clinical trials. More than 500 people have participated in clinical trials sponsored by Neuromod. No other medical device company has invested in gathering so much clinical evidence for the treatment of tinnitus.
Neuromod aims to be a global leader in non-invasive multimodal neuromodulation for unmet needs in neurology, otolaryngology and audiology. Tinnitus occurs in more than 10% of the adult population and can cause significant distress and disability for many people who are unable to escape the constant internal noise.
Lenire® is the first evidence-based, home use, non-invasive treatment for tinnitus that has been evaluated in clinical trials involving more than 500 participants in Ireland and Germany.
Lenire® is easy to use. One or two 30 minute sessions per day for at least 10 weeks can help soothe and relieve tinnitus.
Neuromod plans to expand the commercialisation of CE-marked Lenire® beyond Ireland, first in Germany before expanding to audiology and otolaryngology centres throughout Europe in 2019 and 2020. Activities to secure regulatory clearances outside of Europe are in progress.
Awarded by BSI in 2014, and maintained Up to Date.
Lenire® is available for sale in Dublin, Ireland
Neuromod plans to expand to Germany later in 2019, rolling out throughout Europe from 2020 on.
The Digital Hub
Rainsford St, Dublin 8, D08 R2YP